The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial
- PMID: 24156957
- PMCID: PMC3899700
- DOI: 10.1016/j.fertnstert.2013.08.056
The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial
Abstract
Objective: To summarize baseline characteristics from a large multicenter infertility clinical trial.
Design: Cross-sectional baseline data from a double-blind randomized trial of two treatment regimens (letrozole vs. clomiphene).
Setting: Academic Health Centers throughout the United States.
Patient(s): Seven hundred fifty women with polycystic ovary syndrome (PCOS) and their male partners took part in the study.
Intervention(s): None.
Main outcome measure(s): Historic, biometric, biochemical, and questionnaire parameters.
Result(s): Females averaged 30 years and were obese (body mass index [BMI] 35) with ∼20% from a racial/ethnic minority. Most (87%) were hirsute and nulligravid (63%). Most of the women had an elevated antral follicle count and enlarged ovarian volume on ultrasound. Women had elevated mean circulating androgens, LH-to-FSH ratio (∼2), and antimüllerian hormone levels (8.0 ng/mL). In addition, women had evidence for metabolic dysfunction with elevated mean fasting insulin and dyslipidemia. Increasing obesity was associated with decreased LH-to-FSH levels, antimüllerian hormone levels, and antral follicle counts but increasing cardiovascular risk factors, including prevalence of the metabolic syndrome. Men were obese (BMI 30) and had normal mean semen parameters.
Conclusion(s): The treatment groups were well matched at baseline. Obesity exacerbates select female reproductive and most metabolic parameters. We have also established a database and sample repository that will eventually be accessible to investigators.
Clinical trial registration number: NCT00719186.
Keywords: Insulin resistance; hirsutism; infertility; metabolic syndrome; ovulation induction.
Copyright © 2014 American Society for Reproductive Medicine. All rights reserved.
Similar articles
-
Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome.Hum Reprod. 2017 Aug 1;32(8):1631-1638. doi: 10.1093/humrep/dex227. Hum Reprod. 2017. PMID: 28854590 Free PMC article. Clinical Trial.
-
The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects.Fertil Steril. 2006 Oct;86(4):914-33. doi: 10.1016/j.fertnstert.2006.03.037. Epub 2006 Sep 11. Fertil Steril. 2006. PMID: 16963034 Clinical Trial.
-
A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome.Fertil Steril. 2019 Mar;111(3):571-578.e1. doi: 10.1016/j.fertnstert.2018.11.030. Epub 2019 Jan 22. Fertil Steril. 2019. PMID: 30683591 Clinical Trial.
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.Endocr Pract. 2015 Dec;21(12):1415-26. doi: 10.4158/EP15748.DSCPT2. Endocr Pract. 2015. PMID: 26642102 Review.
-
Ovulatory disorders in women with polycystic ovary syndrome.Clin Obstet Gynaecol. 1985 Sep;12(3):605-32. Clin Obstet Gynaecol. 1985. PMID: 3933879 Review.
Cited by
-
Comparison of sonohysterography to hysterosalpingogram for tubal patency assessment in a multicenter fertility treatment trial among women with polycystic ovary syndrome.J Assist Reprod Genet. 2018 Dec;35(12):2173-2180. doi: 10.1007/s10815-018-1306-2. Epub 2018 Sep 7. J Assist Reprod Genet. 2018. PMID: 30194618 Free PMC article.
-
Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility.Am J Obstet Gynecol. 2017 Aug;217(2):191.e1-191.e19. doi: 10.1016/j.ajog.2017.04.034. Epub 2017 Apr 26. Am J Obstet Gynecol. 2017. PMID: 28455078 Free PMC article.
-
Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype.Am J Obstet Gynecol. 2017 May;216(5):493.e1-493.e13. doi: 10.1016/j.ajog.2017.01.003. Epub 2017 Jan 16. Am J Obstet Gynecol. 2017. PMID: 28104402 Free PMC article. Clinical Trial.
-
Metabolic syndrome in obesity: treatment success and adverse pregnancy outcomes with ovulation induction in polycystic ovary syndrome.Am J Obstet Gynecol. 2021 Sep;225(3):280.e1-280.e11. doi: 10.1016/j.ajog.2021.03.048. Epub 2021 Apr 20. Am J Obstet Gynecol. 2021. PMID: 33852887 Free PMC article. Clinical Trial.
-
Evaluation of Predictors of Response to Ovulation Induction Using Letrozole in Women with Polycystic Ovary Syndrome: A Prospective Cohort Study.J Hum Reprod Sci. 2024 Oct-Dec;17(4):240-245. doi: 10.4103/jhrs.jhrs_133_24. Epub 2024 Dec 23. J Hum Reprod Sci. 2024. PMID: 39831090 Free PMC article.
References
-
- Legro RS, Kunselman AR, Brzyski RG, Casson PR, Diamond MP, Schlaff WD, et al. The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. Contemp Clin Trials. 2012;33:470–481. - PMC - PubMed
-
- Legro RS, Myers ER, Barnhart HX, Carson SA, Diamond MP, Carr BR, et al. The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril. 2006;86:914–933. - PubMed
-
- Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551–566. - PubMed
-
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25. - PubMed
-
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod. 2004;19:41–47. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- U10 HD039005/HD/NICHD NIH HHS/United States
- M01 RR010732/RR/NCRR NIH HHS/United States
- U10 HD33172/HD/NICHD NIH HHS/United States
- U10 HD055944/HD/NICHD NIH HHS/United States
- U54-HD29834/HD/NICHD NIH HHS/United States
- U10 HD38992/HD/NICHD NIH HHS/United States
- U10 HD033172/HD/NICHD NIH HHS/United States
- R01 HD029834/HD/NICHD NIH HHS/United States
- U10 HD027049/HD/NICHD NIH HHS/United States
- U10 HD055942/HD/NICHD NIH HHS/United States
- U10 HD27049/HD/NICHD NIH HHS/United States
- U10HD055942/HD/NICHD NIH HHS/United States
- U10 HD055936/HD/NICHD NIH HHS/United States
- C06 RR016499/RR/NCRR NIH HHS/United States
- U10 HD055925/HD/NICHD NIH HHS/United States
- MO1RR10732/RR/NCRR NIH HHS/United States
- U10 HD38998/HD/NICHD NIH HHS/United States
- U10 HD038998/HD/NICHD NIH HHS/United States
- U10 HD39005/HD/NICHD NIH HHS/United States
- U10 HD038992/HD/NICHD NIH HHS/United States
- P50 HD028934/HD/NICHD NIH HHS/United States
- U10HD055925/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical